105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients.... 105AD7 may be a suitable vaccine for treatment of this disease.
- Mechanism
- Curator reviewed
105AD7 vaccine is a human anti-idiotype which mimics the antigen 791Tgp72. The mechanism of action of the vaccine has recently been clarified. The anti-idiotype is rapidly internalized on antigen presenting cells by Fc mediated endocytosis as both Fab and Ab complexed to alum are processed 1,000 fold less efficiently than whole Ab. Sequencing of the Ab have revealed that the CDR-H3 is hypermutated and contains HLA A1, A3 and A24, and HLA-DR1, 3 and 7 MHC binding motifs.
105AD7 is an antibody-based vaccine that mimics a target (CD55) which is over-expressed in numerous cancers including those of the prostate, colon and pancreas.
- Primary indication
- Investigated for use/treatment in colorectal cancer.Curator reviewed
- Code names
- 105AD7
What you can answer from here — as of April 02, 2025
Which companies are running trials of 105AD7, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account